• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

速尿与螺内酯治疗非氮质血症性肝硬化腹水疗效的随机对照研究。利尿反应与肾素-醛固酮系统活性之间的关系。

Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.

作者信息

Pérez-Ayuso R M, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J

出版信息

Gastroenterology. 1983 May;84(5 Pt 1):961-8.

PMID:6339312
Abstract

Loop and distal diuretics are the basic drugs for the treatment of ascites. Although pharmacologic studies indicate that the natriuretic potency of loop diuretics is much greater than that of distal diuretics, there are no studies comparing the efficacy of these drugs in cirrhosis. Forty nonazotemic cirrhotic patients with ascites and avid sodium retention were randomly allocated into two groups. Group 1 contained 21 patients treated with furosemide; group 2 contained 19 patients treated with spironolactone. The initial doses were 80 and 150 mg/day, respectively. These doses were increased to 160 and 300 mg/day, respectively, if there was no response. Cases not responding to furosemide and spironolactone were later treated with spironolactone and furosemide, respectively. In group 1, 11 of the 21 patients responded to furosemide, while in group 2, 18 of the 19 patients responded to spironolactone (p less than 0.01). Of the 10 patients in group 1 not responding to furosemide, 9 responded later to spironolactone. The diuretic response to furosemide and spironolactone was related to the activity of the renin-aldosterone system. Patients with higher renin and aldosterone did not respond to furosemide and required 300 mg/day of spironolactone to achieve a diuretic response. These results indicate that (a) at the dosages used in the study, spironolactone is more effective than furosemide in nonazotemic cirrhosis with ascites, and (b) the activity of the renin-aldosterone system influences the diuretic response to furosemide and spironolactone in these patients.

摘要

袢利尿剂和远曲小管利尿剂是治疗腹水的基本药物。尽管药理学研究表明袢利尿剂的利钠作用远大于远曲小管利尿剂,但尚无关于这些药物在肝硬化患者中疗效比较的研究。40例无氮质血症的肝硬化腹水患者,伴有明显的钠潴留,被随机分为两组。第1组21例患者接受呋塞米治疗;第2组19例患者接受螺内酯治疗。初始剂量分别为80mg/天和150mg/天。如果无反应,剂量分别增加至160mg/天和300mg/天。对呋塞米和螺内酯无反应的患者,随后分别改用螺内酯和呋塞米治疗。在第1组中,21例患者中有11例对呋塞米有反应,而在第2组中,19例患者中有18例对螺内酯有反应(P<0.01)。第1组中10例对呋塞米无反应的患者,9例后来对螺内酯有反应。对呋塞米和螺内酯的利尿反应与肾素-醛固酮系统的活性有关。肾素和醛固酮水平较高的患者对呋塞米无反应,需要300mg/天的螺内酯才能产生利尿反应。这些结果表明:(a)在本研究使用的剂量下,螺内酯在无氮质血症的肝硬化腹水中比呋塞米更有效;(b)肾素-醛固酮系统的活性影响这些患者对呋塞米和螺内酯的利尿反应。

相似文献

1
Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.速尿与螺内酯治疗非氮质血症性肝硬化腹水疗效的随机对照研究。利尿反应与肾素-醛固酮系统活性之间的关系。
Gastroenterology. 1983 May;84(5 Pt 1):961-8.
2
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.奥曲肽、利尿剂或两者联合治疗对非氮质血症肝硬化腹水患者门静脉血流动力学的影响。
J Clin Gastroenterol. 2006 Apr;40(4):342-6. doi: 10.1097/01.mcg.0000210101.74618.61.
3
Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.影响非氮质血症肝硬化患者腹水利尿剂治疗反应的预测因素。
Scand J Gastroenterol. 1998 Apr;33(4):441-7. doi: 10.1080/00365529850171099.
4
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.螺内酯单用或与呋塞米联用治疗非氮质血症性肝硬化中度腹水:一项疗效与安全性的随机对照研究
J Hepatol. 2003 Aug;39(2):187-92. doi: 10.1016/s0168-8278(03)00188-0.
5
[Biological factors influencing response to diuretics in patients with cirrhosis and ascites].[影响肝硬化腹水患者对利尿剂反应的生物学因素]
Gastroenterol Clin Biol. 2001 Mar;25(3):268-72.
6
A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.非氮质血症肝硬化患者腹水利尿治疗阶梯式护理方法中对螺内酯无反应的病理生理学解释。
Hepatology. 1991 Aug;14(2):231-6.
7
Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis.在利尿反应减弱的失代偿性肝病患者中,低剂量卡托普利联合呋塞米和螺内酯的疗效。
J Hepatol. 1992 May;15(1-2):40-7. doi: 10.1016/0168-8278(92)90009-e.
8
Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.新型袢利尿剂吡咯他尼在肝硬化腹水患者中的应用:利尿反应与血浆醛固酮水平的关系
Gut. 1980 Oct;21(10):855-9. doi: 10.1136/gut.21.10.855.
9
Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.肝硬化腹水:利尿剂抵抗的发病机制及托拉塞米的长期疗效与安全性
Cardiology. 1994;84 Suppl 2:87-98. doi: 10.1159/000176461.
10
[Aldosterone and renin in liver cirrhosis with ascites].[肝硬化腹水患者的醛固酮与肾素]
Schweiz Med Wochenschr. 1977 Dec 3;107(48):1755-9.

引用本文的文献

1
Update on the Complications and Management of Liver Cirrhosis.肝硬化并发症与管理的最新进展
Med Sci (Basel). 2025 Feb 5;13(1):13. doi: 10.3390/medsci13010013.
2
Exploration of sodium homeostasis and pharmacokinetics in bile duct-ligated rats treated by anti-cirrhosis herbal formula plus spironolactone.抗肝硬化中药复方联合螺内酯治疗胆管结扎大鼠钠稳态及药代动力学的研究
Front Pharmacol. 2023 Jan 18;14:1092657. doi: 10.3389/fphar.2023.1092657. eCollection 2023.
3
Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis.
利钠肽治疗肝硬化腹水的疗效与安全性:一项系统评价和荟萃分析。
World J Hepatol. 2022 Apr 27;14(4):827-845. doi: 10.4254/wjh.v14.i4.827.
4
Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding.慢性肝病晚期肝失代偿的管理:腹水、低钠血症和食管胃静脉曲张出血。
Clin Drug Investig. 2022 Jun;42(Suppl 1):25-31. doi: 10.1007/s40261-022-01147-5. Epub 2022 Apr 27.
5
In Vivo Monitoring of Polycythemia Vera Development Reveals Carbonic Anhydrase 1 as a Potent Therapeutic Target.体内监测真性红细胞增多症的发展揭示碳酸酐酶 1 是一个潜在的治疗靶点。
Blood Cancer Discov. 2022 Jul 6;3(4):285-297. doi: 10.1158/2643-3230.BCD-21-0039.
6
Albumin Infusion in Critically Ill COVID-19 Patients: Hemodilution and Anticoagulation.重症 COVID-19 患者的白蛋白输注:血液稀释与抗凝
Int J Mol Sci. 2021 Jul 1;22(13):7126. doi: 10.3390/ijms22137126.
7
Step by Step: Managing the Complications of Cirrhosis.循序渐进:肝硬化并发症的管理
Hepat Med. 2021 May 25;13:45-57. doi: 10.2147/HMER.S278032. eCollection 2021.
8
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.托伐普坦附加给药治疗肝硬化腹水
Int J Mol Sci. 2021 May 25;22(11):5582. doi: 10.3390/ijms22115582.
9
Guidelines on the management of ascites in cirrhosis.肝硬化腹水管理指南。
Gut. 2021 Jan;70(1):9-29. doi: 10.1136/gutjnl-2020-321790. Epub 2020 Oct 16.
10
Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone.茵陈蒿汤与螺内酯的药代动力学和药效学同时相互作用的临床前研究。
BMC Complement Med Ther. 2020 Aug 15;20(1):253. doi: 10.1186/s12906-020-03042-y.